The Latest Clinical Advances in Thrombocytopenia
Platelets are critical elements in the blood stream, supporting hemostasis (defense against bleeding), as well as performing even more complex tasks within networks of biological (immunity) and pathophysiological processes, such as cancer and ischemia/reperfusion injury. Changes in the number (and f...
Saved in:
Other Authors: | , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_78718 | ||
005 | 20220224 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220224s2022 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-2805-2 | ||
020 | |a 9783036528052 | ||
020 | |a 9783036528045 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-2805-2 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
100 | 1 | |a ten Cate, Hugo |4 edt | |
700 | 1 | |a Lammle, Bernhard |4 edt | |
700 | 1 | |a ten Cate, Hugo |4 oth | |
700 | 1 | |a Lammle, Bernhard |4 oth | |
245 | 1 | 0 | |a The Latest Clinical Advances in Thrombocytopenia |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
300 | |a 1 electronic resource (312 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a Platelets are critical elements in the blood stream, supporting hemostasis (defense against bleeding), as well as performing even more complex tasks within networks of biological (immunity) and pathophysiological processes, such as cancer and ischemia/reperfusion injury. Changes in the number (and function) of platelets may have a substantial impact on any of these processes. The "simple" finding of a reduced platelet count (thrombocytopenia) has a history (origin) and a consequence (e.g., bleeding). This book brings together international experts to provide an up-to-date overview of the impact of thrombocytopenia from a clinical perspective. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a thrombotic thrombocytopenic purpura | ||
653 | |a depression | ||
653 | |a resilience | ||
653 | |a quality of life | ||
653 | |a inherited thrombocytopenias | ||
653 | |a platelets | ||
653 | |a bleeding | ||
653 | |a TTP | ||
653 | |a ADAMTS13 | ||
653 | |a treatment | ||
653 | |a diagnosis | ||
653 | |a follow-up | ||
653 | |a review | ||
653 | |a caplacizumab | ||
653 | |a pseudothrombocytopenia | ||
653 | |a hematimetry | ||
653 | |a fluorescence | ||
653 | |a amikacin | ||
653 | |a anticoagulants | ||
653 | |a COVID-19 | ||
653 | |a platelet | ||
653 | |a thrombocytopenia | ||
653 | |a cardiac surgery | ||
653 | |a inflammation | ||
653 | |a biological prosthesis | ||
653 | |a extracorporeal life support | ||
653 | |a heparin-induced thrombocytopenia (HIT) | ||
653 | |a new concepts | ||
653 | |a pathogenesis | ||
653 | |a management | ||
653 | |a immune PF4/heparin/antibody complexes | ||
653 | |a Bayesian diagnostic thinking | ||
653 | |a therapeutic plasma exchange | ||
653 | |a intravenous immunoglobulins (IVIG) | ||
653 | |a immune thrombocytopenia | ||
653 | |a platelet destruction | ||
653 | |a immune tolerance | ||
653 | |a megakaryocytes | ||
653 | |a ITP treatment | ||
653 | |a virus infection | ||
653 | |a thrombocytopathy | ||
653 | |a aggregation | ||
653 | |a HIV | ||
653 | |a SARS-CoV-2 | ||
653 | |a hantavirus | ||
653 | |a coronavirus | ||
653 | |a influenza | ||
653 | |a platelet disorders | ||
653 | |a procoagulant platelets | ||
653 | |a activation endpoints | ||
653 | |a myelodysplastic syndromes (MDS) | ||
653 | |a bone marrow failure (BMF) syndromes | ||
653 | |a aplastic anemia (AA) | ||
653 | |a next-generation sequencing (NGS) | ||
653 | |a platelet function tests | ||
653 | |a platelet count | ||
653 | |a flow cytometry | ||
653 | |a anticoagulation | ||
653 | |a antifibrinolytic | ||
653 | |a antiplatelet | ||
653 | |a cancer | ||
653 | |a thrombopoietin receptor agonist | ||
653 | |a tranexamic acid | ||
653 | |a advanced liver disease | ||
653 | |a bleeding risk | ||
653 | |a cirrhosis | ||
653 | |a hemostasis | ||
653 | |a thrombopoietin receptor agonists/mimetics | ||
653 | |a platelet transfusion guidelines | ||
653 | |a platelet transfusion alternatives | ||
653 | |a platelet additive solutions | ||
653 | |a platelet pathogen inactivation/reduction | ||
653 | |a cold stored platelet concentrates | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4809 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/78718 |7 0 |z DOAB: description of the publication |